Nama's AI scorecard currently rates Illumina Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ILMN's P/E ratio?

Illumina trades at a trailing price-to-earnings ratio of 40.6.

When does ILMN report earnings?

Illumina's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.53.

What is the ILMN price target?

The median analyst price target from 20 analysts is $275.00, with a range of $165.00 – $365.00.

Is ILMN Shariah compliant?

Nama's AAOIFI-style screen reads Illumina as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Illumina (ILMN)

Healthcare · Diagnostics Research · NASDAQ

S&P 500

Illumina (ILMN) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $32.23B, a trailing price-to-earnings ratio of 40.6 and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue declined 0.7% and free cash flow per share grew 33.8%. Nama's AI scorecard rates it Buy, 7.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 7.7/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +121.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-50.2%

How far the last close sits under the highest price of the past five years.

Market cap	$32.23B
Trailing P/E	40.6
Price / book	10.2
Price / sales	7.1
FCF yield	2.8%
Dividend yield	—
Gross margin	66.2%
Operating margin	19.6%
Net margin	19.4%
Revenue growth (YoY)	-0.7%
Revenue growth (3-yr annual)	-1.8%
EPS growth (YoY)	+98.0%
FCF/share growth (YoY)	+33.8%
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

ILMN earnings

Next report: Feb 4, 2027 (Q4 2026, EPS estimate $1.53). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$1.44	$1.36	+5.9%	$1.13B
Q2 2026	Jul 30, 2026	$1.31	$1.23	+6.5%	—
Q1 2026	Apr 30, 2026	$1.15	$1.05	+9.5%	$1.09B
Q4 2025	Feb 5, 2026	$1.35	$1.23	+9.8%	$1.16B

ILMN analyst price target

Median target $275.00 from 20 analysts, ranging $165.00 – $365.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live ILMN data on Nama Insights →

Recent Congressional trades

Illumina trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Mar 9, 2026
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Thomas H. Kean	House	Buy	$1,001 - $15,000	May 15, 2025
Michael C. Burgess	House	Sell	$15,001 - $50,000	Oct 1, 2024
Michael C. Burgess	House	Sell	$15,001 - $50,000	Sep 24, 2024
Thomas H. Kean	House	Buy	$1,001 - $15,000	May 30, 2024
Michael C. Burgess	House	Sell	$1,001 - $15,000	Apr 10, 2024
Michael C. Burgess	House	Sell	$1,001 - $15,000	Mar 22, 2024
Michael C. Burgess	House	Buy	$15,001 - $50,000	Mar 7, 2024
Michael C. Burgess	House	Sell	$1,001 - $15,000	Mar 7, 2024

ILMN FAQ

Is ILMN a buy?: Nama's AI scorecard currently rates Illumina Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ILMN's P/E ratio?: Illumina trades at a trailing price-to-earnings ratio of 40.6.
When does ILMN report earnings?: Illumina's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.53.
What is the ILMN price target?: The median analyst price target from 20 analysts is $275.00, with a range of $165.00 – $365.00.
Is ILMN Shariah compliant?: Nama's AAOIFI-style screen reads Illumina as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.